GI-Cell opens the way for autoimmune disease treatments by obtaining patent for regulatory T cell large-scale culture technology Patent to enhance GI-Cell’s competitiveness in autoimmune disease treatments

공개 2021-11-30 08:14:15

이 기사는 2021년 11월 30일 08:06 더벨 유료페이지에 표출된 기사입니다.

GI-Cell, a South Korea-based company specializing in immune cell therapy, announced on November 29 that it obtained a domestic patent for a large-scale culture technology of regulatory T cells for the treatment of autoimmune diseases. With this patent, GI-Cell is expected to become a leader in the autoimmune disease space in the country.

Regulatory T cells maintain immune system homeostasis through immunosuppression regulation. Regulatory T cells have been in the spotlight as a therapeutic agent for diseases caused by imbalance of the immune system, such as autoimmune diseases. However, the proportion of regulatory T cells among the total T cells is only about 2-3%, making it difficult to separate and culture cells. It is also difficult to develop therapeutic agents because the characteristic properties of regulatory T cells are easily lost during the culturing process. However, GI-Cell succeeded in maintaining highly functional regulatory T cells through its unique and differentiated culture technology with improved productivity.

FoxP3, a key marker that can confirm the function of regulatory T cells, needs to be continuously expressed during cell culture. GI-Cell confirmed that FoxP3 expression was maintained in almost all cells even after the culture was finished, and the regulatory T cells were successfully cultured up to tens of billions of cells in the research stage. In addition, the regulatory T cells under development at GI-Cell have regulated surface receptor expression to target specific organs or inflammatory lesions (Code name GIC302, Brand name Drone Treg), and can more effectively suppress the inflammatory response within the lesion.

Schematic diagram of the mechanism of action of Drone Treg developed to target inflammatory bowel disease. Source: GI-Cell

“This patent is recognized for overcoming the limitations of existing regulatory T cell production technology by manufacturing a large amounts of highly active regulatory T cells through a proprietary culture ancillary material and manufacturing methods without changing any characteristic properties of the cells,” said the inventors of the patent, GI Group Chairman Dr. Myoung Ho Jang and GI-Cell CEO Dr. Chun Pyo Hong. “By utilizing Drone Treg platform technology, GI-Cell will spur the development of cell therapies for various autoimmune diseases.”

GI-Cell was recognized in March as an excellent company in job invention compensation by the Korean Intellectual Property Office. This enabled the company to apply for an expedited examination process and register the patent quickly.

From left, GI Group Chairman Myoung Ho Jang and GI-Cell CEO Chun Pyo Hong. Photo by GI-Cell.
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재 및 재배포 금지 >
주)더벨 주소서울특별시 중구 무교로 6 (을지로 1가) 금세기빌딩 5층대표/발행인성화용 편집인이진우 등록번호서울아00483
등록년월일2007.12.27 / 제호 : 더벨(thebell) 발행년월일2007.12.30청소년보호관리책임자김용관
문의TEL : 02-724-4100 / FAX : 02-724-4109서비스 문의 및 PC 초기화TEL : 02-724-4102기술 및 장애문의TEL : 02-724-4159

더벨의 모든 기사(콘텐트)는 저작권법의 보호를 받으며, 무단 전재 및 복사와 배포 등을 금지합니다.

copyright ⓒ thebell all rights reserved.